Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

5.555 -0.215 (-3.73%)
Streaming Delayed Price Updated: 1:11 PM EDT, Aug 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:RLYB),(NASDAQ:BTAI),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
These companies are in the right place at the right time with the right products. 
Via The Motley Fool
Topics Artificial Intelligence
Why Recursion Pharmaceuticals Stock Tanked on Tuesday
It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest. 
Via The Motley Fool
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Recursion Pharmaceuticals Earnings Preview
 
Via Benzinga
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th
Company to host public (L)earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion (RXRX) Q2 Revenue Jumps 33%
Via The Motley Fool
Topics Artificial Intelligence
Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates
Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to Benzinga Pro. The company reported a second-quarter loss of 41 cents per share,... 
Via Benzinga
Recursion Pharmaceuticals-A (NASDAQ:RXRX) Reports Mixed Q2 2025 Earnings: Revenue Beat but EPS Miss
Recursion Pharmaceuticals (RXRX) reported mixed Q2 2025 results, beating revenue estimates with $19.22M but missing EPS at -$0.41. Shares rose 5.5% pre-market amid clinical progress and Sanofi... 
Via Chartmill
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update
Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) 
From Recursion Pharmaceuticals
Via GlobeNewswire
The Dawn of Hyper-Personalization: How Generative AI is Reshaping Our Digital World
The digital landscape is undergoing a profound transformation as personalized AI, particularly generative AI models, are increasingly being fine-tuned to individual preferences and histories. This... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
2 Beaten-Down Stocks With Incredible Upside Potential
Getting in on the ground floor with these companies might lead to superior returns. 
Via The Motley Fool
Why Recursion Pharmaceuticals Stock Got Mashed on Monday
Investors weren't cheered by news from one of the biotech's rivals. 
Via The Motley Fool
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades.
You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save. 
Via The Motley Fool
Topics Artificial Intelligence Retirement
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants. 
Via Benzinga
Topics Artificial Intelligence ETFs
How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma
AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles. 
Via Benzinga
3 AI Stocks Partnered With Nvidia With Massive Growth Opportunities
Via The Motley Fool
Topics Artificial Intelligence
Biocomputers: The Future of Computing is Alive
In the rapidly evolving world of technology, a groundbreaking frontier is emerging that could redefine the very nature of computation: biocomputers. Unlike traditional computers built from... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Recursion Pharmaceuticals Sees Sharp Gain on AI Biotech Optimism
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) experienced a notable surge in its stock price as investor enthusiasm for artificial intelligence-driven biotechnology reached new highs. The rally comes... 
Via MarketMinute
Topics Artificial Intelligence
Top 2 Health Care Stocks You May Want To Dump This Quarter
 
Via Benzinga
History of Recursion Pharmaceuticals, Inc.: AI‑Driven Drug Discovery Beginnings (NASDAQ:RXRX)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) emerged in the 2010s as one of the pioneers in leveraging artificial intelligence (AI) and advanced data analytics to transform drug discovery and... 
Via MarketMinute
Topics Artificial Intelligence
Is Recursion Pharmaceuticals Gaining or Losing Market Support?
 
Via Benzinga
Why Is Recursion Pharma Stock Surging On Monday?
Recursion's AI-designed cancer drugs REC-3565 and REC-617 show early clinical promise, with one patient responding unexpectedly well to treatment. 
Via Benzinga
Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Jensen Huang's Nvidia Owns 6 Stocks. Here's the Best of the Bunch.
Via The Motley Fool
Topics Artificial Intelligence Initial Public Offering Intellectual Property
10 Under-the-Radar Tech Stocks With Incredible Growth Potential
Just because it's not a household name doesn't mean it's not a magnificent investment. 
Via The Motley Fool
Topics Artificial Intelligence
Here's Why Shares in Recursion Pharmaceuticals Surged Today
Via The Motley Fool
Microchip Technology, Tesla, Humacyte And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Why Is Microcap Rallybio Stock Trading Higher On Tuesday?
Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and milestone payments. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.